For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Blog
This week in health care policy: October 16–23, 2026
Medical innovation FDA approves several innovative treatments. Last week, the FDA granted accelerated approval to GSK’s Jemperli for certain untreated…
Search Posts
Blog
Six takeaways from the recent Obamacare announcements
Every year, health insurers participating in the Exchanges (Obamacare) must announce their planned premium increases for the following year well in advance, so federal…
The Epoch Times
Feds Aim to Tighten Drug Payment Loophole, Save Taxpayers Billions
CEI expert Jeremy Nighohossian was cited by the Epoch Times in their explanation of rule 340b in hospitals. Large hospitals are able to…
Blog
The free market case for AI chatbots in mental health care
Concerns that new technologies may cause negative psychosocial effects are part of a growing public conversation. Questions regarding the intersection between the digital world…
Blog
The fraud problem hidden in the subsidy debate
Last fall, critics argued that under the Republican budget plan, 22.4 million people would see their Obamacare subsidies reduced to prepandemic levels. As Jeremy…
News Release
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring…
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing.
